What Has Been the Growth of the Acute Respiratory Distress Syndrome ARDS Market So Far?
The acute respiratory distress syndrome ards market has seen considerable growth due to a variety of factors.
• The market size of Acute Respiratory Distress Syndrome (ARDS) has experienced swift expansion over the past few years. The market is projected to rise from $1.29 billion in 2024 to $1.42 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 10.4%.
Key factors contributing to the growth during the historic period include advancements in critical care medicine, an increase in the aging population, developments in pulmonary rehabilitation, and the involvement of multidisciplinary care teams.
What Are the Future Growth Projections for the Acute Respiratory Distress Syndrome ARDS Market Size?
The acute respiratory distress syndrome ards market is expected to maintain its strong growth trajectory in upcoming years.
• The acute respiratory distress syndrome (ARDS) market size is expected to see rapid growth in the next few years. It will grow to $2.17 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%.
The growth in the forecast period can be attributed to global healthcare preparedness, vaccine development and infectious disease management, telemedicine and remote monitoring, patient-centered care models. Major trends in the forecast period include artificial lung devices, personalized ventilation strategies, lung protective ventilation, drug therapies for ards subtypes.
What Are The Key Drivers Fueling Growth In The Acute Respiratory Distress Syndrome ARDS Market?
The escalating instances of pneumonia are anticipated to fuel the expansion of the acute respiratory distress syndrome (ARDS) market. Pneumonia, which causes an inflammation in the lungs due to an infection, involves the filling of the lungs' air sacs or alveoli with fluid or pus. The subsequent inflammatory response increases the permeability of blood vessels and causes fluid leakage into the alveoli, obstructing the exchange of oxygen and carbon dioxide and leading to respiratory distress. For example, as per the Centre for Tropical Medicine and Global Health, a health research leader based in the UK, there was a significant surge in pneumonia cases in Kenya, rising to 793,864 in the period of 2022-2023 from 477,186 cases in 2020-2021. Consequently, this increasing severity of pneumonia is driving the ARDS market growth. Remarkably, the Acute Respiratory Distress Syndrome (ARDS) Market is expected to gain from the escalating number of respiratory diseases. Diseases that impact the respiratory system, which includes the airways and lungs, are categorized as respiratory illnesses, and they often result in breathing difficulties. The growth in respiratory diseases, particularly COVID-19, serves as a key contributor to the expansion of the ARDS market. As the number of people suffering from respiratory diseases rise, the need for ARDS treatments and therapies is expected to inflate, fostering market growth. For instance, data from the Bureau of Labor Statistics, a US-based government body, from November 2023 revealed that in 2022, there was a surge in the illness rate among private industry employers, increasing to 45.2 instances per 10,000 FTE workers, a rise from 37.7 instances in 2021. This augment was largely due to a higher rate of respiratory diseases, moving from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Therefore, the growing frequency of respiratory disorders is fuelling the growth of the ARDS market.
What Are The Major Segments Within The Global Acute Respiratory Distress Syndrome ARDS Market?
The acute respiratory distress syndrome (ARDS) market covered in this report is segmented –
1) By Type: Diagnosis, Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users
Subsegments:
1) By Diagnosis: Imaging Tests, Blood Tests, Lung Function Tests, Other Diagnostic Methods
2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care, Other Treatment Options
Pre-Book The Acute Respiratory Distress Syndrome ARDS Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Acute Respiratory Distress Syndrome ARDS Market?
In the acute respiratory distress syndrome (ARDS) market, significant players are working diligently to develop novel drugs and supplements like Aviptadil, HSP90 inhibitors among others to maintain market dominance. Aviptadil, a laboratory-manufactured vasoactive intestinal peptide (VIP), interacts specifically with receptors found on lung alveolar type II cells. For example, Zuventus Healthcare Ltd., a pharmaceutical manufacturing firm from India, launched Aviptadil to manage ARDS in November 2022. This VIP supplement, Aviptadil, enhances respiratory function and reduces death rates for ARDS patients. It achieves these results by the protective and regenerative role it plays on Type-2 Pneumocytes, reinvigorating Type-1 Pneumocytes, escalating surfactant synthesis, and inhibiting IL-6 (interleukin 6) and tumor necrosis factor (TNF)-alpha.
Who Are the Key Players In The Acute Respiratory Distress Syndrome ARDS Market?
Major companies operating in the acute respiratory distress syndrome (ards) market are:
• Johnson & Johnson Services Inc.
• Novartis AG
• GlaxoSmithKline PLC
• Medtronic PLC
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Amgen Inc.
• Fresenius SE & Co. KGaA
• Koninklijke Philips N.V.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• CSL Behring
• Terumo Corporation
• ResMed Inc.
• Smiths Medical Inc.
• Dräger Safety AG & Co. KGaA.
• Getinge AB
• Mallinckrodt PLC
• Masimo Corporation
• United Therapeutics Corporation
• Fisher & Paykel Healthcare Corporation Limited
• Hamilton Medical AG
• Zuventus Healthcare Ltd.
• Windtree Therapeutics Inc.
• Faron Pharmaceuticals Oy
• AcelRx Pharmaceuticals Inc.
What Is The Most Dominant Region In The Acute Respiratory Distress Syndrome ARDS Market?
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
